Articles tagged with: parkinson’s disease
SINEMET® CR 50 mg/200 mg Controlled-Release Tablets
SINEMET® CR 50 mg/200 mg Controlled-Release Tablets
NAME OF THE MEDICINAL PRODUCT
SINEMET® CR 50 mg/200 mg Controlled-Release Tablets
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet of ‘Sinemet CR’ contains carbidopa (equivalent to 50 mg of anhydrous carbidopa) …
REQUIP® & REQUIP XL® – Ropinirole
REQUIP® & REQUIP XL® – Ropinirole
REQUIP® (RE-qwip) (ropinirole) Tablets
REQUIP XL® (RE-qwip) (ropinirole) Extended-release Tablets
PATIENT INFORMATION
If you have Parkinson’s disease, read this side.
If you have Restless Legs Syndrome (RLS), read the other side.
Important Note: REQUIP XL …
PARNATE®
PrPARNATE®
Tranylcypromine Tablets USP
CONSUMER INFORMATION
This leaflet is part III of a three-part “Product Monograph” published for PARNATE®, approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not …
Latuda-lurasidone
Latuda-lurasidone
Package leaflet: Information for the patient
Latuda® 18.5 mg film-coated tablets; Latuda® 37 mg film-coated tablets; Latuda® 74 mg film-coated tablets
This medicine is subject to additional monitoring. This will allow quick identification of new safety …
Invega-Paliperidone
Invega-Paliperidone
Package leaflet: Information for the user
INVEGA 1.5 mg prolonged-release tablets; INVEGA 3 mg prolonged-release tablets; INVEGA 6 mg prolonged-release tablets; INVEGA 9 mg prolonged-release tablets; INVEGA 12 mg prolonged-release tablets
Read all of this leaflet carefully …
Oxazepam 10mg and 15mg tablets
Oxazepam 10mg and 15mg tablets
PATIENT INFORMATION LEAFLET
Oxazepam 10mg and 15mg tablets
Read all of this leaflet carefully before you start taking this medicine.
Keep this leaflet. You may need to read it again.
If you have any further …
